Marked increase of CYP24A1 mRNA level in hepatocellular carcinoma cell lines following vitamin D administration

Anticancer Research

Volumn 32, Issue 11, 2012, Pages 4791-4796

  Horvath, Evelin ^a   Lakatos, Péter ^a   Balla, Bernadett ^a   Kósa, János Pál ^a   Tóbiás, Bálint ^a   Jozilan, Hasan ^a   Borka, Katalin ^a   Horváth, Henrik Csaba ^a   Kovalszky, Ilona ^a   Szalay, Ferenc ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

1,25 dihydroxyvitamin D3; CYP24A1; Hepatocellular carcinoma; HepG2; mRNA expression

Indexed keywords

CALCITRIOL; COMPLEMENTARY DNA; CYTOCHROME P450; CYTOCHROME P450 24A1; CYTOCHROME P450 24B1; MESSENGER RNA; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR;

ADOLESCENT; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CARCINOMA CELL; CELL GROWTH; CONTROLLED STUDY; DRUG RESPONSE; ENZYME ACTIVATION; GENE ACTIVATION; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; LIVER CELL CARCINOMA; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VITAMIN D METABOLISM;

CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STEROID HYDROXYLASES; VITAMIN D;

EID: 84872659710     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Spina CS, Tangpricha V, Uskokovic M, Adorinic L, Maehr H and Holick MF: Vitamin D and cancer. Anticancer Res 26: 2515- 2524, 2006.
2. Luo W, Chen J, Zhang X and Wang W: Regulatory mechanism of EB1089 for hepatocarcinoma cell proliferation. Wei Sheng Yen Chiu 33: 140-143, 2004.
3. 3 and its analogues, EB1089 and CB1093, profoundly inhibit the in vitro proliferation of the human hepatoblastoma cell line HepG2. ANZ J Surg 71: 414-417, 2001.
4. Dalhoff K, Dancey J, Astrup L, Skovsgaard T, Hamberg KJ, Lofts FJ, Rosmorduc O, Erlinger S, Bach Hansen J, Steward WP, Skov T, Burcharth F and Evans TR: A phase II study of the vitamin D analogue seocalcitol in patients with inoperable hepatocellular carcinoma. Br J Cancer 89: 252-257, 2003.
5. Ghous Z, Akhter J, Pourgholami MH and Morris DL: Inhibition of hepatocellular cancer by EB1089: in vitro and in vivo study. Anticancer Res 28(6A): 3757-3761, 2008.
6. Cagnon L, Wagaman P, Bartenschlager R, Pietschmann T, Gao T, Kneteman NM, Tyrrell DL, Bahl C, Niven P, Lee S and Simmen KA: Application of the trak-C HCV core assay for monitoring antiviral activity in HCV replication systems. J Virol Methods 118(1): 23-31, 2004.
7. Frese M, Barth K, Kaul A, Lohmann V, Schwärzle V and Bartenschlager R: Hepatitis C virus RNA replication is resistant to tumour necrosis factor-α. J Gen Virol 84: 1253-1259, 2003.
8. Lohmann V, Körner F, Koch J, Herian U, Theilmann L and Bartenschlager R: Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285: 110-113, 1999.
9. Knowles BB, Howe CC and Aden DP: Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen. Science 209: 497-499, 1980.
10. Hsu SL, Lin YF and Chou CK: Retinoic acid biphasically regulates the gene expression of hepatitis B virus surface antigen in human hepatoma Hep3B cells. J Biol Chem 268: 23093-23097, 1993.
11. El-Serag HB: Hepatocellular carcinoma. N Engl J Med 365: 1118-1127, 2011.
12. WHO, Cancer Fact Sheet No. 296, World Health Organization, www.who.int/mediacentre/factsheets, 2006.
13. Colston KW, Berger U and Coombes RC: Possible role for vitamin D in controlling breast cancer proliferation. Lancet 1: 188-189, 1989.
14. Akhter J, Goerdel M and Morris DL: A vitamin D 3 analogue (EB1089) inhibits in vitro cellular proliferation of human colon cancer cells. Br J Surg 83: 229-230, 1996.
15. 3 and malignant melanoma: the presence of receptors and inhibition of cell growth in culture. Endocrinology 108(3): 1083-1086, 1981.
16. 3. Cancer Lett 151(1): 97-102, 2000.
17. 3 in lipiodol for the treatment of hepatocellular carcinoma: cellular, animal and clinical studies. J Steroid Biochem Mol Biol 89- 90(1-5): 513-518, 2004.
18. 3 in lipiodol: Pilot study in patients with hepatocellular carcinoma. Int J Oncol 21(4): 901-906, 2002.
19. 3 down-regulates CYP27B1 and induces CYP24A1 in colon cells. Mol Cell Endocrinol 263(1-2): 55-64, 2007.
20. Parise RA, Egorin MJ, Kanterewicz B, Taimi M, Petkovich M, Lew AM, Chuang SS, Nichols M, El-Hefnawy T and Hershberger PA: CYP24, the enzyme that catabolizes the antiproliferative agent vitamin D, is increased in lung cancer. Int J Cancer 119(8): 1819-1828, 2006.
21. Balla B, Kósa JP, Tobiás B, Halászlaki C, Takács I, Horváth H, Speer G, Nagy Z, Horányi J, Járay B, Székely E and Lakatos P: Marked increase in CYP24A1 gene expression in human papillary thyroid cancer. Thyroid 21(4): 459-60, 2011.
22. Lopes N, Sousa B, Martins D, Gomes M, Vieira D, Veronese LA, Milanezi F, Paredes J, Costa JL and Schmitt F: Alterations in vitamin D signalling and metabolic pathways in breast cancer progression: A study of VDR, CYP27B1 and CYP24A1 expression in benign and malignant breast lesions. BMC Cancer 10: 483, 2010.
23. Kloss M, Fischer D, Thill M, Friedrich M, Cordes T, Salehin D, Diedrich K and Köster F: Vitamin D, calcidiol and calcitriol regulate vitamin D metabolizing enzymes in cervical and ovarian cancer cells. Anticancer Res 30(11): 4429-4434, 2010.
24. Muindi JR, Yu WD, Ma Y, Engler KL, Kong RX, Trump DL and Johnson CS: CYP24A1 inhibition enhances the antitumor activity of calcitriol. Endocrinology 151(9): 4301-4312, 2010.
25. Albertson DG, Ylstra B, Segraves R, Collins C, Dairkee SH, Kowbel D, Kuo WL, Gray JW and Pinkel D: Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene. Nat Genet 25(2): 144-146, 2000.
26. Horváth HC, Lakatos P, Kósa JP, Bácsi K, Borka K, Bises G, Nittke T, Hershberger PA, Speer G and Kállay E: The candidate oncogene CYP24A1: A potential biomarker for colorectal tumorigenesis. J Histochem Cytochem 58(3): 277-285, 2010.
27. Bitetto D, Fattovich G, Fabris C, Ceriani E, Falleti E, Fornasiere E, Pasino M, Ieluzzi D, Cussigh A, Cmet S, Pirisi M and Toniutto P: Complementary role of vitamin D deficiency and the interleukin-28B rs12979860 C/T polymorphism in predicting antiviral response in chronic hepatitis C. Hepatology 53(4): 1118-1126, 2011.
28. Anderson MG, Nakane M, Ruan X, Kroeger PE and Wu-Wong JR: Expression of VDR and CYP24A1 mRNA in human tumors. Cancer Chemother Pharmacol 57(2): 234-240, 2006.
29. 3. Mol Endocrinol 20: 1231-1247, 2006.
30. Cordes T, Diesing D, Becker S, Diedrich K, Reichrath J and Friedrich M: Modulation of MAPK ERK1 and ERK2 in VDR-positive and -negative breast cancer cell lines. Anticancer Res 26(4A): 2749-2753, 2006.